Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus | Zendy

Matthias Richard | Zendy; Ana Victoria Gutiérrez | Zendy; Albertus Viljoen | Zendy; Daniela Rodriguez-Rincon | Zendy; Françoise Roquet-Banères | Zendy; Mickaël Blaise | Zendy; Isobel Everall | Zendy; Julian Parkhill | Zendy; R. Andres Floto | Zendy; Laurent Kremer | Zendy

Open Access

Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus

Author(s) -

Matthias Richard,

Ana Victoria Gutiérrez,

Albertus Viljoen,

Daniela Rodriguez-Rincon,

Françoise Roquet-Banères,

Mickaël Blaise,

Isobel Everall,

Julian Parkhill,

R. Andres Floto,

Laurent Kremer

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01316-18

Subject(s) - clofazimine , bedaquiline , mycobacterium abscessus , tetr , microbiology and biotechnology , medicine , mycobacterium tuberculosis , tuberculosis , mycobacterium , nontuberculous mycobacteria , biology , immunology , leprosy , pathology , genetics , gene , repressor , transcription factor

New therapeutic approaches are needed againstMycobacterium abscessus , a respiratory mycobacterial pathogen that evades efforts to successfully treat infected patients. Clofazimine and bedaquiline, two drugs used for the treatment of multidrug-resistant tuberculosis, are being considered as alternatives for the treatment of lung diseases caused byM. abscessus .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research